Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Portage Biotech Inc (PRTG – Research Report) and Virios Therapeutics (VIRI – Research Report).
Portage Biotech Inc (PRTG)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Portage Biotech Inc, with a price target of $22.00. The company’s shares closed last Monday at $7.28, close to its 52-week low of $4.62.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Portage Biotech Inc with a $24.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Virios Therapeutics (VIRI)
H.C. Wainwright analyst Sean Lee CFA downgraded Virios Therapeutics to Hold today. The company’s shares closed last Monday at $2.00, close to its 52-week low of $1.92.
According to TipRanks.com, CFA has 0 stars on 0-5 stars ranking scale with an average return of
Virios Therapeutics has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRTG:
- H.C. Wainwright Remains a Buy on Vista Gold (VGZ)
- H.C. Wainwright Sticks to Their Buy Rating for TOMI Environmental Solutions (TOMZ)
- Gevo (GEVO) Receives a Rating Update from a Top Analyst
- Elys Game Technology (ELYS) Receives a Buy from H.C. Wainwright
- MRNA, PFE, NVAX, BNTX: Pharma Stocks Shiver as the U.S. President Calls Pandemic ‘Over’
